| Day One , 13 Jan 2011 |
| 08:30 |
Registration |
Overview of World Railway Development |
| 09:00 |
Has China become the R&D hub for the global pharmaceutical industry? |
| 09:30 |
Strategically choosing the R&D location to optimize the local resources while reduce the financial pressure |
| 10:00 |
Build up the lucrative research alliances to operate more effectively and to achieve sustainable R&D outcomes |
| 10:30 |
Tea break |
| 10:45 |
Realizing tangible value from Merger and Acquisition to truly achieve the business goal |
| 11:15 |
Take an even closer look at India: opportunities to be further explored and experience learnt |
| 11:45 |
Set up a smart R&D pipeline to prepare for the end of the ‘blockbuster era’ |
| 12:15 |
Wisely balancing Small Molecules and Biologics to enjoy today’s success and embrace tomorrow’s prospect |
| 12:45 |
Luncheon |
| 14:00 |
How to enhance the innovation capability to secure the competitive advantage |
| 14:30 |
Intellectual Property Right (IPR) challenges and solutions in conducting R&D in China |
Advanced Technologies Leading to the Future |
| 15:00 |
Patent Drugs and Generics—the war on the patent expiration |
| 15:30 |
Branded generics—an alternative winning strategy after the patent expiries? |
| 16:00 |
Tea break |
| 16:15 |
Grasp the opportunity of the patent expirations: Chinese industry players’ choices |
| 16:45 |
Ensure pharmaceutical supply chain effectiveness |
| 17:15 |
End of Day One |
| Day Two ,14 Jan 2011 |
| 08:30 |
Registration |
Be Intelligent: Factors Attracting Passengers to the Rail |
| 09:00 |
Personalized medicine—shifting from the fairytale of blockbuster |
| 09:30 |
Biomarkers and translational medicine for innovative drug development |
| 10:00 |
Tea break |
| 10:15 |
The competitive landscape in biosimilars and a comparison between US/EU and China’s capability |
Risk Management in Rail Industry |
| 10:45 |
Good Laboratories Practice (GLP) in China—current and future prospect |
| 11:15 |
Key factors to be considered for clinical development in emerging markets |
| 11:45 |
Early stage drug safety strategies and risk management—maximizing opportunities towards achieving clinical success |
| 12:15 |
Reducing business risk with the right Contract Research Organization (CRO) partner |
| 12:45 |
Luncheon |
| 14:00 |
Integrate CRO for pharmaceutical research and development to optimize the investment and maximize the outcomes |
| 14:30 |
How to effectively recruit and retain patients for the clinical trials |
| 15:00 |
Successfully and smartly implement the data management to improve the efficiency of your clinical trial activities |
| 15:30 |
The emerging role of Phase IV clinical research—regulatory issues, strategic drivers and overall trends |
| 16:00 |
Tea break |
| 16:15 |
Conducting the effective Post-Marketing Surveillance (PMS) to ensure the drug safety and secure the market status in long run |
| 16:45 |
Successfully determine the best manufacturing solution—make or buy? |
| 17:15 |
End of the Conference |
关于峰会 .gif){kind=small}
.gif){kind=small}